Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 4
2008 1
2009 1
2010 3
2011 4
2012 5
2013 4
2014 6
2015 4
2016 7
2017 18
2018 13
2019 21
2020 25
2021 24
2022 28
2023 27
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean chunxiasu (3 results)?
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao M, Jiang T, Liu X, Mao S, Zhou F, Li X, Zhao C, Chen X, Su C, Ren S, Zhou C. Qiao M, et al. Among authors: su c. J Thorac Oncol. 2021 Aug;16(8):1267-1288. doi: 10.1016/j.jtho.2021.04.003. Epub 2021 Apr 26. J Thorac Oncol. 2021. PMID: 33915248 Free article. Review.
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease.
Zhou C, Qin Y, Zhao W, Liang Z, Li M, Liu D, Bai L, Chen Y, Chen Y, Cheng Y, Chu T, Chu Q, Deng H, Dong Y, Fang W, Fu X, Gao B, Han Y, He Y, Hong Q, Hu J, Hu Y, Jiang L, Jin Y, Lan F, Li Q, Li S, Li W, Li Y, Liang W, Lin G, Lin X, Liu M, Liu X, Liu X, Liu Z, Lv T, Mu C, Ouyang M, Qin J, Ren S, Shi H, Shi M, Su C, Su J, Sun D, Sun Y, Tang H, Wang H, Wang K, Wang K, Wang M, Wang Q, Wang W, Wang X, Wang Y, Wang Z, Wang Z, Wu L, Wu D, Xie B, Xie M, Xie X, Xie Z, Xu S, Xu X, Yang X, Yin Y, Yu Z, Zhang J, Zhang J, Zhang J, Zhang X, Zhang Y, Zhong D, Zhou Q, Zhou X, Zhou Y, Zhu B, Zhu Z, Zou C, Zhong N, He J, Bai C, Hu C, Li W, Song Y, Zhou J, Han B, Varga J, Barreiro E, Park HY, Petrella F, Saito Y, Goto T, Igai H, Bravaccini S, Zanoni M, Solli P, Watanabe S, Fiorelli A, Nakada T, Ichiki Y, Berardi R, Tsoukalas N, Girard N, Rossi A, Passaro A, Hida T, Li S, Chen L, Chen R. Zhou C, et al. Among authors: su c. Transl Lung Cancer Res. 2023 Aug 30;12(8):1661-1701. doi: 10.21037/tlcr-23-339. Epub 2023 Aug 24. Transl Lung Cancer Res. 2023. PMID: 37691866 Free PMC article. Review.
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.
He J, Su C, Liang W, Xu S, Wu L, Fu X, Zhang X, Ge D, Chen Q, Mao W, Xu L, Chen C, Hu B, Shao G, Hu J, Zhao J, Liu X, Liu Z, Wang Z, Xiao Z, Gong T, Lin W, Li X, Ye F, Liu Y, Ma H, Huang Y, Zhou J, Wang Z, Fu J, Ding L, Mao L, Zhou C. He J, et al. Among authors: su c. Lancet Respir Med. 2021 Sep;9(9):1021-1029. doi: 10.1016/S2213-2600(21)00134-X. Epub 2021 Jul 21. Lancet Respir Med. 2021. PMID: 34280355 Clinical Trial.
Emerging insights to lung cancer drug resistance.
Su C. Su C. Cancer Drug Resist. 2022 Jun 21;5(3):534-540. doi: 10.20517/cdr.2022.61. eCollection 2022. Cancer Drug Resist. 2022. PMID: 36176761 Free PMC article.
Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study.
Deng H, Zhou J, Chen H, Cai X, Zhong R, Li F, Cheng B, Li C, Jia Q, Zhou C, Petersen RH, Rocco G, Brunelli A, Ng CSH, D'Amico TA, Su C, He J, Liang W, Zhu B; AME Thoracic Surgery Collaborative Group. Deng H, et al. Among authors: su c. Int J Surg. 2024 Jan 1;110(1):238-252. doi: 10.1097/JS9.0000000000000774. Int J Surg. 2024. PMID: 37755384 Free PMC article.
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.
Wang L, Luo Y, Ren S, Zhang Z, Xiong A, Su C, Zhou J, Yu X, Hu Y, Zhang X, Dong X, Meng S, Wu F, Hou X, Dai Y, Song W, Li B, Wang ZM, Xia Y, Zhou C. Wang L, et al. Among authors: su c. J Thorac Oncol. 2024 Mar;19(3):465-475. doi: 10.1016/j.jtho.2023.10.014. Epub 2023 Oct 23. J Thorac Oncol. 2024. PMID: 37879536 Free article. Clinical Trial.
Immunotherapy resistance of lung cancer.
Yu X, Han C, Su C. Yu X, et al. Among authors: su c. Cancer Drug Resist. 2022 Feb 8;5(1):114-128. doi: 10.20517/cdr.2021.101. eCollection 2022. Cancer Drug Resist. 2022. PMID: 35582531 Free PMC article.
Recent advances in immunotherapy for lung cancer.
Wang Q, Su C, Zhou C. Wang Q, et al. Among authors: su c. Cancer Innov. 2023 Feb 24;2(1):18-24. doi: 10.1002/cai2.55. eCollection 2023 Feb. Cancer Innov. 2023. PMID: 38090371 Free PMC article. Review.
181 results